Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is poised for significant growth, with expectations that WAKIX sales will increase from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company has a strong pipeline of products, including pitolisant-GR, which aims to improve patient adherence by eliminating the need for dose titration, as evidenced by successful outcomes in their dosing optimization study. With multiple registrational trials set to either initiate or report results in the next 12 to 18 months, alongside a solid financial position to support internal research and development, Harmony represents a compelling growth opportunity in the neurology sector.

Bears say

Harmony Biosciences Holdings Inc. recently reported disappointing results from its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint due to a higher-than-expected placebo response, raising concerns about the efficacy of this candidate. The company faces several risks that could negatively impact its revenue growth, including increased competition in the sodium oxybate market affecting WAKIX sales, a potential slowdown in new patient additions, and the uncertainty surrounding the success of ongoing clinical trials for various neurological conditions. Additionally, the potential for earlier-than-expected competition from generic pitolisant compounds further complicates the company's future revenue projections and overall market positioning.

HRMY has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 7 analysts, HRMY has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.